SCHEMBL2983847

SCHEMBL2983847

Nc1nc2c(ncn2O)c(=O)[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 6/20 0.57
TK1 P04183 2/20 0.57
PNP P00491 7/20 0.56
BLM P54132 2/20 0.56
USP2 O75604 1/20 0.56
TSHR P16473 1/20 0.56
EDNRA P25101 1/20 0.56
HTR2A P28223 1/20 0.56
RECQL P46063 1/20 0.56
HBB P68871 1/20 0.56
HSD17B10 Q99714 1/20 0.56
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
CYP3A4 P08684 1/20 0.53
NFKB1 P19838 1/20 0.53
VCP P55072 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HIF1A Q16665 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL9697806 0.98 XDH (0.56) XDHTK1PNPBLMUSP2
SCHEMBL986800 0.82 XDH (0.60) XDHTK1PNPBLMUSP2
SCHEMBL15005119 0.81 XDH (0.59) XDHTK1PNPBLMUSP2
SCHEMBL27667185 0.81 XDH (0.63) XDHTK1PNPBLMUSP2
SCHEMBL41787 0.81 XDH (0.59) XDHTK1PNPBLMUSP2
SCHEMBL27923065 0.80 XDH (0.55) XDHTK1PNPBLMUSP2
SCHEMBL27541246 0.80 XDH (0.58) XDHTK1PNPBLMUSP2
SCHEMBL2051364 0.79 XDH (0.57) XDHTK1PNPBLMUSP2
SCHEMBL10835122 0.79 XDH (0.61) XDHTK1PNPBLMUSP2
SCHEMBL22533906 0.79 XDH (0.57) XDHTK1PNPBLMUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115769078-A Compositions with improved specificity and sensitivity for ovarian cancer assessment 艾思彼拉妇女保健公司 2023-03-07 CN claimed
CN-106442958-A Atmospheric particulate toxicity study method and system thereof 北京大学 2017-02-22 CN claimed
US-20260139247-A1 ENGINEERED ENVELOPED VECTORS AND METHODS OF USE THEREOF GIGAMUNE INC (US) 2026-05-21 US disclosed
US-12631621-B2 Ligand discovery and gene delivery via retroviral surface display MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2026-05-19 US disclosed
US-12631622-B2 Ligand discovery and gene delivery via retroviral surface display MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2026-05-19 US disclosed
US-20260029398-A1 LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2026-01-29 US disclosed
US-20260029399-A1 LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2026-01-29 US disclosed
US-12501868-B2 Haploid induction compounds and methods for use thereof WIMI BIOTECHNOLOGY (HAINAN) CO., LTD. (CN) 2025-12-23 US disclosed
US-12455280-B2 Ligand discovery and gene delivery via retroviral surface display MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-10-28 US disclosed
US-12371689-B2 Engineered enveloped vectors and methods of use thereof GIGAMUNE, INC. (US) 2025-07-29 US disclosed
EP-4580664-A1 ENGINEERED ENVELOPED VECTORS AND METHODS OF USE THEREOF Gigamune, Inc. (US) 2025-07-09 EP disclosed
US-20030167524-A1 Methods for the production of multimeric protein complexes, and related compositions SEMBIOSYS GENETICS, INC. (CA) 2003-09-04 US disclosed
US-20030093832-A1 Methods for the production of multimeric immunoglobulins, and related compositions SEMBIOSYS GENETICS INC. (CA) 2003-05-15 US disclosed
WO-2002050289-A9 METHODS FOR THE PRODUCTION OF MULTIMERIC PROTEINS, AND RELATED COMPOSITIONS SEMBIOSYS GENETICS INC (CA) 2003-04-17 WO disclosed
WO-2003002564-A1 IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES MEDIVIR AB (SE) 2003-01-09 WO disclosed
WO-2002050289-A1 METHODS FOR THE PRODUCTION OF MULTIMERIC PROTEINS, AND RELATED COMPOSITIONS SEMBIOSYS GENETICS, INC. (CA) 2002-06-27 WO disclosed
WO-2002030266-A2 DETECTION OF DNA DAMAGE ESA, INC. (US) 2002-04-18 WO disclosed
WO-2002031189-A2 MODEL SYSTEM FOR THE VIVO STUDY OF APOPTOSIS EIRX THERAPEUTIC LIMITED (IE) 2002-04-18 WO disclosed
US-20020037303-A1 Thioredoxin and thioredoxin reductase containing oil body based products SEMBIOSYS GENETICS INC. (CA) 2002-03-28 US disclosed
WO-1996024688-A1 DIAGNOSTICS BASED ON DNA DUPLEX REPAIR MOSAIC TECHNOLOGIES (US) 1996-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139247-A1 ENGINEERED ENVELOPED VECTORS AND METHODS OF USE THEREOF TMIGD3, TMPRSS11D, TMED2 XDH 1291/4885TK1 2648/4885PNP 2068/4885
US-20260029399-A1 LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY VSIG8, TMIGD3, LDLR XDH 4303/4885TK1 1675/4885PNP 3119/4885
US-20260029398-A1 LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY LDLR, TMIGD3, VSIG8 XDH 3946/4885TK1 1717/4885PNP 2954/4885
US-12631622-B2 Ligand discovery and gene delivery via retroviral surface display VSIG8, TMIGD3, CD4 XDH 4183/4885TK1 1260/4885PNP 3251/4885
US-12631621-B2 Ligand discovery and gene delivery via retroviral surface display TMIGD3, LDLR, VSIG8 XDH 3987/4885TK1 1395/4885PNP 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.